No Data
April 4th [Today's Investment Strategy]
[FISCO Selected Stocks] 【Material Stocks】 Onward Holdings <8016> 517 yen (4/3) Clothing manufacturer. Brands include "23区", "組曲", and "iCB" among others. The financial results for the fiscal year ending February 2025 have been announced. The operating profit is 10.1 billion yen (a 9.8% decrease from the previous year). The previous Financial Estimates were 12.5 billion yen (an 11.0% increase). It has been noted that challenges remain in addressing climate change, etc. The operating profit forecast for the fiscal year ending February 2026 is 11.5 billion yen (a 13.3% increase from the previous year). Operating profit for the entire Overseas business.
List of convertible stocks (Part 1) [List of Parabolic Signal convertible stocks]
○ List of stocks transitioning to Buy in the market Code Stock Name Closing Price SAR Main Board <2681> Geo HD 1911 1742 <2685> Adastria 3020 2832 <2726> Pal HD 3295 2999 <3038> Kobe Bussan 3592 3384 <3635> Koei Tecmo 2117 1957 <4502> Takeda Pharma 4540 4352 <6967> Shinko Electric 8994 6411 <7447> Nagai
The Nikkei average is down about 965 yen, with the decline rate of selected stocks such as Resona HD, Sumitomo Pharma, and Mizuho among the top.
On the morning of the 3rd, the Nikkei average stock price was around 34,760 yen, down about 965 yen from the previous day. President Trump announced the details of the mutual tariffs on the 2nd local time, imposing a 24% tax on Japan. Concerns were raised about the impact of these tariffs on the economy, and the yen appreciated in the foreign exchange market, leading to a pre-market sell-off. At 9:02 AM, the price dropped to 34,102 yen, a decrease of 1,623 yen and 87 sen. After that, there was a sense of overselling and buying aimed at a rebound.
StemRIM's Stroke Drug Clears Key Hurdle in Global Trial
Shionogi Submits NDA for COVID-19 Antiviral Ensitrelvir to FDA
Fanpep - Clinical trials for the skin ulcer treatment drug and pollen allergy Vaccine will Start in 2025.
FanPep Co., Ltd. <4881> is a biotech venture established in 2013 with the aim of commercializing research成果 on functional peptides from the Graduate School of Medicine at Osaka Universities. Through independently developed antibody-inducing peptide technology based on functional peptides, the company is working on the development of pharmaceuticals that can serve as alternatives to expensive antibody Pharmaceuticals. Furthermore, in October 2022, it became a subsidiary of Anti-Aging Peptides Co., Ltd. (currently FanPep Healthcare), expanding into non-pharmaceuticals such as Cosmetics.